AFINITOR is a once-daily oral inhibitor of mTOR (mammalian target of rapamycin) for patients with advanced renal cell carcinoma (RCC) whose disease has progressed on or after treatment with VEGF-targeted therapy
Afinitor International Website | For Healthcare Professionals Outside the U.S. | US Residents
Professional Resources
Novartis remains committed to providing healthcare professionals with information and tools that enhance your ability to use AFINITOR® (everolimus) tablets more efficiently and effectively. Explore these resources to find the information you need to enhance your knowledge of AFINITOR and optimize your patients' treatment.
